Oxaliplatin Does Not Benefit Older Patients With Metastatic Colorectal Cancer
Oxaliplatin did not prolong progression-free survival and was associated with more adverse events.
American Society of Clinical Oncology Gastrointestinal (ASCO GI) Symposium
Stopping Adjuvant Treatment Early May Decrease DFS, OS in Stage III Colon Cancer
Early treatment discontinuation was associated with a decrease in survival, but early oxaliplatin discontinuation was not.
First Positive First-Line Immuno-Chemotherapy Results for Biliary Tract Cancer
Adding durvalumab to gemcitabine and cisplatin improved progression-free and overall survival.
Eryaspase Does Not Improve PFS or OS in Advanced Pancreatic Cancer
The median overall survival was 7.5 months in the eryaspase arm and 6.7 months in the chemotherapy-alone arm.
STRIDE Regimen Extends Survival in Unresectable Hepatocellular Carcinoma
The median overall survival was 16.4 months with STRIDE and 13.8 months with sorafenib.
TACE Improves Efficacy of Lenvatinib in Advanced Hepatocellular Carcinoma
TACE improved responses and survival outcomes.
COVID-19 Pandemic Did Not Affect Care of Pancreatic Cancer Patients
Patients with pancreatic ductal adenocarcinoma may have been spared the COVID-related delays in care seen for other cancers, according to researchers.
Sintilimab Improves Response to Chemotherapy in Advanced Pancreatic Cancer
The improvement in response did not translate to a survival benefit.
Adjuvant S-1 Improves OS, Is Labelled New Standard in Biliary Tract Cancer
Adjuvant S-1 improved survival over surgery alone.
Outcomes Similar With Etoposide or Irinotecan Plus Cisplatin in Gastrointestinal Neuroendocrine Carcinoma
Both platinum-based chemotherapy regimens are standard of care for digestive system neuroendocrine carcinoma.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ASCO GI 2022
Loading... 
Loading...